The Effectiveness of Liraglutide in Nonalcoholic Fatty Liver Disease Patients with Type 2 Diabetes Mellitus Compared to Sitagliptin and Pioglitazone

The Effectiveness of Liraglutide in Nonalcoholic Fatty Liver Disease Patients with Type 2 Diabetes Mellitus Compared to Sitagliptin and Pioglitazone

Background. Liraglutide leading to improve not only glycaemic control but also liver inflammation in non-alcoholic fatty liver disease (NAFLD) patients. Aims. The aim of this study is to elucidate the effectiveness of liraglutide in NAFLD patients with type 2 diabetes mellitus (T2DM) compared to sit...

Full description

Saved in:

Bibliographic Details
Main Authors:	Takamasa Ohki, Akihiro Isogawa, Masahiko Iwamoto, Mitsuru Ohsugi, Haruhiko Yoshida, Nobuo Toda, Kazumi Tagawa, Masao Omata, Kazuhiko Koike
Format:	Article
Language:	English
Published:	Wiley 2012-01-01
Series:	The Scientific World Journal
Online Access:	http://dx.doi.org/10.1100/2012/496453
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Effects of Pioglitazone on Nonalcoholic Fatty Liver Disease in the Absence of Constitutive Androstane Receptor Expression
by: Hwa Young Ahn, et al.
Published: (2018-01-01)

Liraglutide Attenuates Nonalcoholic Fatty Liver Disease through Adjusting Lipid Metabolism via SHP1/AMPK Signaling Pathway
by: Peng Yu, et al.
Published: (2019-01-01)

Deciphering the Topology of Sitagliptin Using an Integrated Approach
by: Renny Mathew, et al.
Published: (2025-01-01)

Sitagliptin: a potential drug for the treatment of COVID-19?
by: Bardaweel Sanaa K., et al.
Published: (2021-06-01)

Comparison of Liver Biopsy and Transient Elastography based on Clinical Relevance
by: Ryota Masuzaki, et al.
Published: (2008-01-01)

An Exceedingly Rare Case of Liraglutide-Induced Liver Injury
by: Swetha Parvataneni, et al.
Published: (2021-01-01)

Liraglutide Decreases Liver Fat Content and Serum Fibroblast Growth Factor 21 Levels in Newly Diagnosed Overweight Patients with Type 2 Diabetes and Nonalcoholic Fatty Liver Disease
by: Xinyue Li, et al.
Published: (2021-01-01)

Pioglitazone Attenuates Vascular Fibrosis in Spontaneously Hypertensive Rats
by: Dengfeng Gao, et al.
Published: (2012-01-01)

Comprehensive cDNA cloning and putative feature analysis of endogenous cellulases possessed by the Pacific oyster, Crassostrea gigas.
by: Manabu Wen-Liu Tanimura, et al.
Published: (2025-01-01)

Ameliorative Impact of Liraglutide on Chronic Intermittent Hypoxia-Induced Atrial Remodeling
by: Jun Wang, et al.
Published: (2022-01-01)

Efficacy and Safety of Sitagliptin for the Treatment of New-Onset Diabetes after Renal Transplantation
by: Brian P. Boerner, et al.
Published: (2014-01-01)

Adjunctive Sitagliptin Therapy in Postoperative Cardiac Surgery Patients: A Pilot Study
by: Marcia L. Brackbill, et al.
Published: (2012-01-01)

Neuroprotective and Anti-inflammatory Effects of Pioglitazone on Traumatic Brain Injury
by: Mohammad Yassin Zamanian, et al.
Published: (2022-01-01)

Study of Postprandial Lipaemia in Type 2 Diabetes Mellitus: Exenatide versus Liraglutide
by: Maria Voukali, et al.
Published: (2014-01-01)

Effect of Liraglutide on Serum TSH Levels in Patients with NAFLD and its Underlying Mechanisms
by: JiaoJiao Ye, et al.
Published: (2022-01-01)

Glucagon-Like Peptide-1 Receptor Agonist Liraglutide Ameliorates the Development of Periodontitis
by: Noritaka Sawada, et al.
Published: (2020-01-01)

Pioglitazone Ameliorates Neuron Loss in the Cortex after Aluminum-Treatment in Rats
by: Ali Rafati, et al.
Published: (2015-01-01)

Simultaneous Estimation of Glimepiride, Rosiglitazone and Pioglitazone Hydrochloride in the Pharmaceutical Dosage Form
by: Freddy H. Havaldar, et al.
Published: (2010-01-01)

Rosiglitazone and Pioglitazone Alter Aromatase Kinetic Properties in Human Granulosa Cells
by: Takako Araki, et al.
Published: (2011-01-01)

Effect and Safety of Pioglitazone-Metformin Tablets in the Treatment of Newly Diagnosed Type 2 Diabetes Patients with Nonalcoholic Fatty Liver Disease in Shaanxi Province: A Randomized, Double-Blinded, Double-Simulated Multicenter Study
by: Fu Jianfang, et al.
Published: (2023-01-01)

Therapeutic Potential of Liraglutide for Diabetes–Periodontitis Comorbidity: Killing Two Birds with One Stone
by: Man Yang, et al.
Published: (2022-01-01)

Effect of Metformin and Sitagliptin on Doxorubicin-Induced Cardiotoxicity in Rats: Impact of Oxidative Stress, Inflammation, and Apoptosis
by: Mina Thabet Kelleni, et al.
Published: (2015-01-01)

Basal-Supported Oral Therapy with Sitagliptin Counteracts Rebound Hyperglycemia Caused by GLP-1 Tachyphylaxis
by: Shu Meguro, et al.
Published: (2014-01-01)

Effects and Potential Mechanisms of Pioglitazone on Lipid Metabolism in Obese Diabetic KKAy Mice
by: Jun Peng, et al.
Published: (2014-01-01)

Modulation of Adipocytokines Production and Serum NEFA Level by Metformin, Glimepiride, and Sitagliptin in HFD/STZ Diabetic Rats
by: Mohamed I. Saad, et al.
Published: (2015-01-01)

Sitagliptin and the Blood-Retina Barrier: Effects on Retinal Endothelial Cells Manifested Only after Prolonged Exposure
by: Anja Jäckle, et al.
Published: (2020-01-01)

Factors Correlated to the Renoprotective Effect of Sitagliptin in Patients with Type 2 Diabetes Mellitus: Retrospective Observational Study
by: Pirawan Khunkit, et al.
Published: (2024-01-01)

Effects of Sitagliptin Treatment on Dysmetabolism, Inflammation, and Oxidative Stress in an Animal Model of Type 2 Diabetes (ZDF Rat)
by: Liliana Ferreira, et al.
Published: (2010-01-01)

Liraglutide Promotes Osteoblastic Differentiation in MC3T3-E1 Cells by ERK5 Pathway
by: Yue Sun, et al.
Published: (2020-01-01)

Current Treatment Options for Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis
by: Melanie D Beaton
Published: (2012-01-01)

Pioglitazone versus Rosiglitazone: Effects on Lipids, Lipoproteins, and Apolipoproteins in Head-to-Head Randomized Clinical Studies
by: Mark A. Deeg, et al.
Published: (2008-01-01)

Pioglitazone Attenuates Drug-Eluting Stent-Induced Proinflammatory State in Patients by Blocking Ubiquitination of PPAR
by: Zhongxia Wang, et al.
Published: (2016-01-01)

Dipeptidyl-Peptidase 4 Inhibitor Sitagliptin Ameliorates Hepatic Insulin Resistance by Modulating Inflammation and Autophagy in ob/ob Mice
by: Wenbin Zheng, et al.
Published: (2018-01-01)

Expert Opinion on Fixed Dose Combination of Dapagliflozin Plus Sitagliptin for Unmet Cardiovascular Benefits in Type 2 Diabetes Mellitus
by: Soumitra Ray, et al.
Published: (2024-04-01)

A Randomized Controlled Clinical Trial of Lifestyle Intervention and Pioglitazone for Normalization of Glucose Status in Chinese with Prediabetes
by: Yingying Luo, et al.
Published: (2022-01-01)

Corrigendum to “Pioglitazone Attenuates Drug-Eluting Stent-Induced Proinflammatory State in Patients by Blocking Ubiquitination of PPAR”
by: Zhongxia Wang, et al.
Published: (2019-01-01)

Extractive Spectrophotometric Method for Determination of Pioglitazone Hydrochloride in Raw Material and Tablets Using Ion-Pair Formation
by: Massoud Amanlou, et al.
Published: (2010-01-01)

Liraglutide Regulates the Kidney and Liver in Diabetic Nephropathy Rats through the miR-34a/SIRT1 Pathway
by: Shan Xiao, et al.
Published: (2021-01-01)

Liraglutide alleviates high-fat diet-induced kidney injury in mice by regulating the CaMKKβ/AMPK pathway
by: Yingli Xuan, et al.
Published: (2024-12-01)

Meta-analysis of the clinical efficacy of liraglutide in treating type 2 diabetes mellitus complicated with non-alcoholic fatty liver disease
by: Yuan-Yuan Xu, et al.
Published: (2024-09-01)